Randomized, Placebo-Controlled Trial of Biofeedback for the Treatment of Rumination

被引:35
|
作者
Barba, Elizabeth [1 ,2 ,3 ]
Accarino, Anna [1 ,2 ,3 ]
Soldevilla, Alfredo [4 ]
Malagelada, Juan-R [1 ,2 ,3 ]
Azpiroz, Fernando [1 ,3 ]
机构
[1] Univ Hosp Vall Hebron, Digest Syst Res Unit, Bellaterra, Spain
[2] Ciberehd, Bellaterra, Spain
[3] Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain
[4] Univ Politecn Cataluna, Dept Phys, Barcelona, Spain
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷 / 07期
关键词
HIGH-RESOLUTION MANOMETRY; FUNCTIONAL DYSPEPSIA; DOUBLE-BLIND; SIMETHICONE; DISTENSION; MECHANISMS; DIAGNOSIS; SYMPTOMS; EPISODES;
D O I
10.1038/ajg.2016.197
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: We previously demonstrated that rumination is produced by an unperceived, somatic response to food ingestion, and we developed an original biofeedback technique based on electromyography (EMG)-guided control of abdomino-thoracic muscular activity. Our aim was to demonstrate the superiority of biofeedback vs. placebo for the treatment of rumination. METHODS: Randomized, placebo-controlled trial performed in a referral center. Consecutive patients who fulfilled the Rome III criteria for rumination (18 women, 6 men; 19-79 years age) were selected and all included in the study; 1 patient assigned to placebo withdrew because of an unrelated accident. Abdomino-thoracic muscle activity after a challenge meal was recorded by EMG. The patients in the biofeedback group were shown the signal and instructed to control muscle activity, whereas the patients in the placebo group were not shown the signal and were given oral simethicone. Each patient underwent 3 sessions over a 10-day period. Main outcome: number of rumination events as measured by questionnaires for 10 consecutive days before and after intervention. RESULTS: Patients on biofeedback (n = 12) but not on placebo (n = 11) effectively learned to reduce intercostal activity (by 51 +/- 6% vs. 10 +/- 7% increment on placebo; P < 0.001) and anterior wall muscle activity (by 52 +/- 4% vs. 9 +/- 2% increment on placebo; P < 0.001). Biofeedback treatment resulted in a 74 +/- 6% reduction in rumination activity (from 29 +/- 6 before to 7 +/- 2 daily events after intervention) vs. 1 +/- 14% on placebo; P = 0.001 (from 21 +/- 2 before to 21 +/- 4 daily events after intervention). CONCLUSIONS: Rumination can be effectively corrected by biofeedback-guided control of abdomino-thoracic muscular activity.
引用
收藏
页码:1007 / 1013
页数:7
相关论文
共 50 条
  • [21] A Randomized Placebo-Controlled Trial of Montelukast in Maintenance Treatment of Eosinophilic Esophagitis
    Alexander, Jeffrey A.
    Karthik, Ravi
    Enders, Felicity
    Geno, Debra M.
    Kryzer, Lori
    Mara, Kristin
    Smyrk, Thomas
    Katzka, David A.
    GASTROENTEROLOGY, 2016, 150 (04) : S19 - S19
  • [22] Olanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial
    McElroy, Susan L.
    Nelson, Erik B.
    Welge, Jeffrey A.
    Kaehler, Laura
    Keck, Paul E., Jr.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (03) : 433 - 440
  • [23] Escitalopram in the Treatment of Adolescent Depression: A Randomized Placebo-Controlled Multisite Trial
    Emslie, Graham J.
    Ventura, Daniel
    Korotzer, Andrew
    Tourkodimitris, Stavros
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2009, 48 (07): : 721 - 729
  • [24] BlephEx-treatment for blepharitis: a prospective randomized placebo-controlled trial
    Siegel, Helena
    Merz, Annika
    Gross, Nikolai
    Bruender, Marie-Christine
    Boehringer, Daniel
    Reinhard, Thomas
    Maier, Philip
    BMC OPHTHALMOLOGY, 2024, 24 (01)
  • [25] Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial
    Dogan, Nurettin Ozgur
    Pekdemir, Murat
    Yilmaz, Serkan
    Yaka, Elif
    Karadas, Adnan
    Durmus, Ugur
    Avcu, Nazire
    Kockan, Esra
    ACTA NEUROLOGICA SCANDINAVICA, 2019, 139 (04): : 334 - 339
  • [26] Tocilizumab for the Treatment of Giant Cell Arteritis - a Randomized Placebo-Controlled Trial
    Adler, Sabine
    Reichenbach, Stephan
    Kuchen, Stefan
    Wermelinger, Felix
    Dan, Diana
    Villiger, Peter M.
    Seitz, Michael
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [27] Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial
    K. Mann
    K. Ackermann
    A. Diehl
    D. Ebert
    G. Mundle
    H. Nakovics
    T. Reker
    G. Richter
    L. G. Schmidt
    M. Driessen
    K. Rettig
    K. Opitz
    B. Croissant
    Psychopharmacology, 2006, 184 : 115 - 121
  • [28] A Randomized Placebo-Controlled Trial of Swallowed Fluticasone as Treatment of Eosinophilic Esophagitis
    Alexander, Jeffrey
    Jung, Kee Wook
    Arora, Amindra
    Enders, Felicity
    Francis, Dawn
    Kita, Hirohito
    Romero, Yvonne
    Katzka, David
    Smyrk, Thomas
    Talley, Nicholas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S21 - S22
  • [29] A randomized, placebo-controlled trial of repaglinide in the treatment of type 2 diabetes
    Goldberg, RB
    Brodows, RG
    Damsbo, P
    DIABETES, 1998, 47 : A98 - A98
  • [30] A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
    Friedman, Scott L.
    Ratziu, Vlad
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    Aithal, Guruprasad P.
    Caballeria, Juan
    Francque, Sven
    Farrell, Geoffrey
    Kowdley, Kris V.
    Craxi, Antonio
    Simon, Krzysztof
    Fischer, Laurent
    Melchor-Khan, Liza
    Vest, Jeffrey
    Wiens, Brian L.
    Vig, Pamela
    Seyedkazemi, Star
    Goodman, Zachary
    Wong, Vincent Wai-Sun
    Loomba, Rohit
    Tacke, Frank
    Sanyal, Arun
    Lefebvre, Eric
    HEPATOLOGY, 2018, 67 (05) : 1754 - 1767